Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.

ABSTRACT:

Lessons learned

Vandetanib at a dose of 300 mg orally every day plus bortezomib 1.3 mg/m² intravenously on days 1, 4, 8, and 11 could be administered safely.Assessing outcomes in 17 patients with medullary thyroid cancer, investigators considered the combination to be more difficult to administer than single-agent vandetanib and that achieving better outcomes was unlikely. Consequently, a planned phase II study was terminated early.

Background

The proto-oncogene RET (REarranged during Transfection) has a critical role in the pathogenesis of medullary thyroid cancer (MTC). Vandetanib (V), a multitargeted tyrosine kinase inhibitor approved for the treatment of MTC, is thought to inhibit RET in MTC. Supported by preclinical studies demonstrating that bo

SUBMITTER: Del Rivero J 

PROVIDER: S-EPMC6324636 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature